Chronic hepaititis due to HCV Compensated liver cirroshis due to HCV
Conditions
Interventions
Maviret (Glecaprevir 100mg, Pibrentasvir 40 mg) 3T/day, once Treatment period 1)Chronich haptits C due to genotype 1 and 2:8 weeks, however, if the patients have history of treatment failure with dire
Sponsors
Kanazawa University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients with chronic hepatitis or compensated cirrhosis due to HCV infection 2)Patients 20 years of age or older at the time of informed consent
Exclusion criteria
Exclusion criteria: 1)Patients with a history of hypersensitivity to any of the ingredients of Maviret (CONTRAINDICATIONS in the package insert) 2)Patients who are using any of contraindicated co-medications listed in the package insert 3)Patients with severe liver dysfunction (Child-Pugh classification C) (CONTRAINDICATIONS in the package insert) 4)Patients who have received treatment for hepatcellular carcinoma within the past 12 weeks
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Identification of New Biomarkers for Prediction of Hepatocellular Carcinoma after Eliminating Hepatitis C Virus | — |
Secondary
| Measure | Time frame |
|---|---|
| 1)Identification of new biomarkers for prediction of hepatocellular carcinoma after eliminating Hepatitis C Virus 2)Analysis on HCV amino acid/nucleotide sequences (core, NS5A, and NS5B) 3)Analysis on cytokines in peripheral blood 4)Analysis of gene profiling of liver obatained by liver biopsy 5)Analysis of Fibroscan 6)Analysis glucose/lipid metabolism 7)Analysis of gene profiling of peripheral blood lymphocyte 8)Quantification of laminin gamma 2 monomer in serum | — |
Countries
Japan
Contacts
Public ContactTetsuro Shimakami
Kanazawa University Department of Gastroenterology
Outcome results
None listed